

1. Abraham-Marin MI, Cortes-Luna Cf, Alvarez-Rivera G et al. (2007) Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. *Graefes Arch Clin Exp Ophthalmol* 245:651-655
2. Ach T, Dawczynski J, Konigsdorffer E et al. (2007) [Subjective sensations after intravitreal injection of bevacizumab]. *Klin Monatsbl Augenheilkd* 224:180-184
3. Adan A, Mateo C, Navarro R et al. (2007) Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. *Retina* 27:1180-1186
4. Adan A, Navarro M, Casaroli-Marano Rp et al. (2007) Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome. *Graefes Arch Clin Exp Ophthalmol* 245:1873-1875
5. Aggio Fb, Farah Me, De Melo Gb et al. (2007) Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. *Eye* 21:408-409
6. Aggio Fb, Farah Me, Silva Wc et al. (2007) Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. *Graefes Arch Clin Exp Ophthalmol* 245:215-220
7. Aggio Fb, Melo Gb, Hofling-Lima Al et al. (2006) Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration. *Acta Ophthalmol Scand* 84:831-833
8. Ahmadieh H, Moradian S, Malihi M (2005) Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab. *Int Ophthalmol* 26:191-193
9. Ahmadieh H, Ramezani A, Shoeibi N et al. (2007) Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. *Graefes Arch Clin Exp Ophthalmol*
10. Ahmadieh H, Taei R, Soheilian M et al. (2007) Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. *BMC Ophthalmol* 7:10
11. Ahmadieh H, Vafi N (2007) Dramatic response of choroidal neovascularization associated with choroidal osteoma to the intravitreal injection of bevacizumab (Avastin). *Graefes Arch Clin Exp Ophthalmol* 245:1731-1733
12. Aisenbrey S, Ziemssen F, Volker M et al. (2007) Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 245:941-948
13. Algvere Pv, Steen B, Seregard S et al. (2007) A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. *Acta Ophthalmol Scand*
14. Amselem L, Cervera E, Diaz-Llopis M et al. (2007) Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up. *Eye* 21:566-567
15. Amselem L, Diaz-Llopis M, Cervera E et al. (2008) [Intravitreal injection of bevacizumab (Avastin(R)) for retinal angiomatous proliferation.]. *Arch Soc Esp Oftalmol* 83:53-56
16. Amselem L, Montero J, Diaz-Llopis M et al. (2007) Intravitreal bevacizumab (Avastin) injection in ocular ischemic syndrome. *Am J Ophthalmol* 144:122-124
17. Anonymous (2006) [Comments on current therapeutic possibilities for neovascular age-related macula degeneration]. *Klin Monatsbl Augenheilkd* 223:271-278
18. Arevalo Jf, Fromow-Guerra J, Quiroz-Mercado H et al. (2007) Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. *Ophthalmology* 114:743-750

19. Arevalo Jf, Garcia-Amaris Ra, Roca Ja et al. (2007) Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group. *J Cataract Refract Surg* 33:2098-2105
20. Arevalo Jf, Maia M, Flynn Hw, Jr. et al. (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. *Br J Ophthalmol* 92:213-216
21. Arevalo Jf, Wu L, Sanchez Jg et al. (2007) Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up. *Eye*
22. Arias L, Caminal Jm, Rubio M et al. (2007) Retinal pigment epithelial tears after intravitreal bevacizumab injection for predominantly classic choroidal neovascularization. *Eur J Ophthalmol* 17:992-995
23. Arriola-Villalobos P, Donate-Lopez J, Calvo-Gonzalez C et al. (2008) Intravitreal bevacizumab (Avastin) for radiation retinopathy neovascularization. *Acta Ophthalmol Scand* 86:115-116
24. Augustin Aj, Puls S, Offermann I (2007) Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. *Retina* 27:133-140
25. Avery Rl (2006) Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. *Retina* 26:352-354
26. Avery Rl, Pearlman J, Pieramici Dj et al. (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. *Ophthalmology* 113:1695 e1691-1615
27. Avery Rl, Pieramici Dj, Rabena Md et al. (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. *Ophthalmology* 113:363-372 e365
28. Azad R, Chandra P (2007) Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. *Indian J Ophthalmol* 55:319; author reply 320
29. Azad R, Chandra P, Gupta R (2007) The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration. *Indian J Ophthalmol* 55:441-443
30. Bakri Sj, Cameron Jd, Mccannel Ca et al. (2006) Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. *Am J Ophthalmol* 142:162-164
31. Bakri Sj, Donaldson Mj, Link Tp (2006) Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. *Eye* 20:1474-1475
32. Bakri Sj, Ekdawi Ns (2007) Intravitreal triamcinolone and bevacizumab combination therapy for refractory choroidal neovascularization with retinal angiomatous proliferation. *Eye*
33. Bakri Sj, Larson Ta, Edwards Ao (2008) Intraocular inflammation following intravitreal injection of bevacizumab. *Graefes Arch Clin Exp Ophthalmol*
34. Bakri Sj, Patel Sp (2007) Retinal pigment epithelial tear following intravitreal bevacizumab. *Eye* 21:424-425
35. Bakri Sj, Pulido Js, Mccannel Ca et al. (2007) Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. *Eye*
36. Bakri Sj, Snyder Mr, Reid Jm et al. (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). *Ophthalmology* 114:2179-2182
37. Bakri Sj, Snyder Mr, Reid Jm et al. (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). *Ophthalmology* 114:855-859
38. Bashshur Zf, Bazarbachi A, Schakal A et al. (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. *Am J Ophthalmol* 142:1-9

39. Bashshur Zf, Haddad Za, Schakal A et al. (2008) Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: A One-year Prospective Study. *Am J Ophthalmol* 145:249-256
40. Bashshur Zf, Schakal A, Hamam Rn et al. (2007) Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. *Arch Ophthalmol* 125:1357-1361
41. Batioglu F, Astam N, Ozmert E (2008) Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. *Int Ophthalmol* 28:59-61
42. Beer Pm, Wong Sj, Hammad Am et al. (2006) Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. *Retina* 26:871-876
43. Bennett JI, Thomas S, Olson JI et al. (2007) Treatment of nonarteritic anterior ischemic optic neuropathy with intravitreal bevacizumab. *J Neuroophthalmol* 27:238-240
44. Bhatnagar P, Freund Kb, Spaide Rf et al. (2007) Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum. *Retina* 27:897-902
45. Bhatnagar P, Spaide Rf, Takahashi Bs et al. (2007) Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration. *Retina* 27:846-850
46. Bom Aggio F, Eid Farah M, Melo Gb (2006) Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. *Acta Ophthalmol Scand* 84:713-714
47. Brantley Ma, Jr., Fang Am, King Jm et al. (2007) Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. *Ophthalmology* 114:2168-2173
48. Brown Dm, Regillo Cd (2007) Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. *Am J Ophthalmol* 144:627-637
49. Byeon Sh, Kwon Ya, Oh Hs et al. (2007) Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema. *J Ocul Pharmacol Ther* 23:387-394
50. Chan Ck, Lin Sg (2007) Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment. *Eur J Ophthalmol* 17:674-676
51. Chan Ck, Meyer Ch, Gross Jg et al. (2007) Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. *Retina* 27:541-551
52. Chan Wm, Lai Ty, Liu Dt et al. (2007) Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. *Am J Ophthalmol* 143:977-983
53. Chan Wm, Lai Ty, Liu Dt et al. (2007) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. *Ophthalmology* 114:2190-2196
54. Chang Lk, Sarraf D (2007) Tears of the retinal pigment epithelium: an old problem in a new era. *Retina* 27:523-534
55. Charbel Issa P, Holz Fg, Scholl Hp (2007) Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. *Ophthalmology* 114:1736-1742

56. Charles S, Rosenfeld Pj, Gayer S (2007) Medical consequences of stopping anticoagulant therapy before intraocular surgery or intravitreal injections. *Retina* 27:813-815
57. Chen Cy, Wong Ty, Heriot Wj (2007) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. *Am J Ophthalmol* 143:510-512
58. Chen E, Kaiser Rs, Vander Jf (2007) Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. *Retina* 27:445-450
59. Chen E, Park Ch (2006) Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. *Retina* 26:699-700
60. Chieh Jj, Fekrat S (2007) Large subretinal hemorrhage after intravitreal bevacizumab (Avastin) for age-related macular degeneration. *Ann Ophthalmol (Skokie)* 39:51-52
61. Chong Nv, Adewoyin T (2007) Intravitreal injection: balancing the risks. *Eye* 21:313-316
62. Chung Ej, Kim Jh, Ahn Hs et al. (2007) Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. *Graefes Arch Clin Exp Ophthalmol* 245:1727-1730
63. Chung Ej, Koh Hj (2007) Retinal detachment with macular hole following combined photodynamic therapy and intravitreal bevacizumab injection. *Korean J Ophthalmol* 21:185-187
64. Cleary Ca, Jungkim S, Ravikumar K et al. (2008) Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. *Eye* 22:82-86
65. Colucciello M (2008) Intravitreal Bevacizumab and Triamcinolone Acetonide Combination Therapy for Exudative Neovascular Age-Related Macular Degeneration: Short-Term Optical Coherence Tomography Results. *J Ocul Pharmacol Ther*
66. Cordero Coma M, Sobrin L, Onal S et al. (2007) Intravitreal bevacizumab for treatment of uveitic macular edema. *Ophthalmology* 114:1574-1579 e1571
67. Costa Ra, Jorge R, Calucci D et al. (2006) Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. *Invest Ophthalmol Vis Sci* 47:4569-4578
68. Costa Ra, Jorge R, Calucci D et al. (2007) Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. *Retina* 27:141-149
69. Costa Ra, Jorge R, Calucci D et al. (2007) Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). *Graefes Arch Clin Exp Ophthalmol* 245:1273-1280
70. Costagliola C, Romano Mr, Dell'omo R et al. (2007) Intravitreal bevacizumab for the treatment of retinal angiomatous proliferation. *Am J Ophthalmol* 144:449-451
71. Dafer Rm, Schneck M, Friberg Tr et al. (2007) Intravitreal ranibizumab and bevacizumab: a review of risk. *Semin Ophthalmol* 22:201-204
72. De Clercq C, Snyers B, Guagnini Ap et al. (2007) [In Process Citation]. *Bull Soc Belge Ophtalmol*:15-21
73. Dell'omo R, Kulkarni A, Franks Wa (2007) Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity. *Acta Ophthalmol Scand*
74. Dhalla Ms, Shah Gk, Blinder Kj et al. (2006) Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. *Retina* 26:988-993

75. Diaz-Llopis M, Amselem L, Cervera E et al. (2007) [Intravitreal injection of bevacizumab for pseudophakic cystoid macular edema resistant to steroids]. *Arch Soc Esp Oftalmol* 82:447-450
76. Ekdawi Ns, Bakri Sj (2007) Intravitreal triamcinolone and bevacizumab combination therapy for macular edema due to central retinal vein occlusion refractory to either treatment alone. *Eye* 21:1128-1130
77. Emerson Mv, Lauer Ak (2007) Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. *BioDrugs* 21:245-257
78. Emerson Mv, Lauer Ak, Flaxel Cj et al. (2007) Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. *Retina* 27:439-444
79. Eren E, Kucukerdonmez C, Yilmaz G et al. (2007) Regression of neovascular posterior capsule vessels by intravitreal bevacizumab. *J Cataract Refract Surg* 33:1113-1115
80. Falkenstein Ia, Cheng L, Freeman Wr (2007) Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). *Retina* 27:1044-1047
81. Faria E Arantes Te, Nascimento Vp, Maia Junior Ode O et al. (2007) [Bevacizumab (Avastin) in treatment of choroidal neovascularization secondary to age-related macular degeneration: a case report]. *Arq Bras Oftalmol* 70:1016-1020
82. Feiner L, Barr Ee, Shui Yb et al. (2006) Safety of intravitreal injection of bevacizumab in rabbit eyes. *Retina* 26:882-888
83. Ferrara Dc, Koizumi H, Spaide Rf (2007) Early bevacizumab treatment of central retinal vein occlusion. *Am J Ophthalmol* 144:864-871
84. Finger Pt (2007) Anti-VEGF bevacizumab (Avastin) for radiation optic neuropathy. *Am J Ophthalmol* 143:335-338
85. Finger Pt, Chin K (2007) Anti-vascular endothelial growth factor bevacizumab (avastin) for radiation retinopathy. *Arch Ophthalmol* 125:751-756
86. Friedlander Sm, Welch Rm (2006) Vanishing disc neovascularization following intravitreal bevacizumab (avastin) injection. *Arch Ophthalmol* 124:1365
87. Frimpong-Boateng A, Varde Ma, Rufer F et al. (2008) [Intravitreal administration of triamcinolone and bevacizumab for pigment epithelial detachment in conjunction with AMD.]. *Ophthalmologe*
88. Fung Ae, Rosenfeld Pj, Reichel E (2006) The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. *Br J Ophthalmol* 90:1344-1349
89. Gamulescu Ma, Framme C, Sachs H (2007) RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD. *Graefes Arch Clin Exp Ophthalmol* 245:1037-1040
90. Geitzenauer W, Michels S, Prager F et al. (2006) [Early effects of systemic and intravitreal bevacizumab (avastin) therapy for neovascular age-related macular degeneration]. *Klin Monatsbl Augenheilkd* 223:822-827
91. Gelisken F, Ziemssen F, Voelker M et al. (2006) Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration. *Acta Ophthalmol Scand* 84:833-834
92. Gelisken F, Ziemssen F, Voelker M et al. (2008) Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration. *Eye*
93. Ghajarnia M, Kurup S, Eller A (2007) The therapeutic effects of intravitreal bevacizumab in a patient with recalcitrant idiopathic polypoidal choroidal vasculopathy. *Semin Ophthalmol* 22:127-131
94. Gheith Me, Siam Ga, De Barros Ds et al. (2007) Role of intravitreal bevacizumab in neovascular glaucoma. *J Ocul Pharmacol Ther* 23:487-491

95. Giansanti F, Virgili G, Bini A et al. (2007) Intravitreal bevacizumab therapy for choroidal neovascularization secondary to age-related macular degeneration: 6-month results of an open-label uncontrolled clinical study. *Eur J Ophthalmol* 17:230-237
96. Gibran Sk, Sachdev A, Stappler T et al. (2007) Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin). *Br J Ophthalmol* 91:602-604
97. Goff Mj, Johnson Rn, Mcdonald Hr et al. (2007) Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. *Retina* 27:432-438
98. Gomi F, Nishida K, Oshima Y et al. (2007) Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone. *Am J Ophthalmol* 143:507-510
99. Gomi F, Sawa M, Sakaguchi H et al. (2008) Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. *Br J Ophthalmol* 92:70-73
100. Hoh Ae, Schaal Kb, Dithmar S (2007) [Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria and Switzerland]. *Ophthalmologie* 104:290-294
101. Hollands H, Wong J, Bruen R et al. (2007) Short-term intraocular pressure changes after intravitreal injection of bevacizumab. *Can J Ophthalmol* 42:807-811
102. Hsu J, Kaiser Rs, Sivalingam A et al. (2007) Intravitreal bevacizumab (avastin) in central retinal vein occlusion. *Retina* 27:1013-1019
103. Hughes Ms, Sang Dn (2006) Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. *Ophthalmic Surg Lasers Imaging* 37:446-454
104. Iliev Me, Domig D, Wolf-Schnurrbursch U et al. (2006) Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. *Am J Ophthalmol* 142:1054-1056
105. Inan Uu, Avci B, Kusbeci T et al. (2007) Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. *Invest Ophthalmol Vis Sci* 48:1773-1781
106. Iriyama A, Chen Yn, Tamaki Y et al. (2007) Effect of anti-VEGF antibody on retinal ganglion cells in rats. *Br J Ophthalmol* 91:1230-1233
107. Isaacs Tw, Barry C (2006) Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). *Clin Experiment Ophthalmol* 34:802-803
108. Ishikawa K, Honda S, Tsukahara Y et al. (2007) Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. *Eye*
109. Iturralde D, Spaide Rf, Meyerle Cb et al. (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. *Retina* 26:279-284
110. Jaissle Gb, Ziemssen F, Petermeier K et al. (2006) [Bevacizumab for treatment of macular edema secondary to retinal vein occlusion.]. *Ophthalmologie*
111. Jaissle Gb, Ziemssen F, Petermeier K et al. (2006) [Bevacizumab for treatment of macular edema secondary to retinal vein occlusion]. *Ophthalmologie* 103:471-475
112. Jalil A, Fenerty C, Charles S (2007) Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. *Eye* 21:1541
113. Jamerson Sc, Arunagiri G, Ellis Bd et al. (2008) Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to pseudotumor cerebri. *Int Ophthalmol*

114. Joeres S, Heussen Fm, Treziak T et al. (2007) Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation. *Graefes Arch Clin Exp Ophthalmol* 245:1597-1602
115. Joeres S, Kaplowitz K, Brubaker Jw et al. (2008) Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration. *Ophthalmology* 115:347-354 e342
116. Jonas Jb, Harder B, Spandau Uh et al. (2006) Bevacizumab for occult subfoveal neovascularization in age-related macular degeneration. *Eur J Ophthalmol* 16:774-775
117. Jonas Jb, Libondi T, Ihloff Ak et al. (2007) Visual acuity change after intravitreal bevacizumab for exudative age-related macular degeneration in relation to subfoveal membrane type. *Acta Ophthalmol Scand* 85:563-565
118. Jonas Jb, Libondi T, Von Baltz S et al. (2007) Intravitreal bevacizumab for vitreous haemorrhage. *Acta Ophthalmol Scand*
119. Jonas Jb, Spandau Uh, Rensch F et al. (2007) Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. *J Ocul Pharmacol Ther* 23:240-242
120. Jonas Jb, Spandau Uh, Schlichtenbrede F (2007) Intravitreal bevacizumab for filtering surgery. *Ophthalmic Res* 39:121-122
121. Jonas Jb, Spandau Uh, Schlichtenbrede F (2008) Short-term complications of intravitreal injections of triamcinolone and bevacizumab. *Eye*
122. Jonas Jb, Spandau Uh, Schlichtenbrede F et al. (2007) Intravitreal bevacizumab combined with cataract surgery for treatment of exudative macular degeneration. *J Ocul Pharmacol Ther* 23:599-600
123. Jorge R, Costa Ra, Calucci D et al. (2006) Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). *Retina* 26:1006-1013
124. Jorge R, Costa Ra, Calucci D et al. (2007) Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. *Graefes Arch Clin Exp Ophthalmol* 245:1045-1048
125. Kahook My, Schuman Js, Noecker Rj (2006) Intravitreal bevacizumab in a patient with neovascular glaucoma. *Ophthalmic Surg Lasers Imaging* 37:144-146
126. Kang Jh, Park Ka, Chung Se et al. (2007) Retinal angiomatous proliferation and intravitreal bevacizumab injection. *Korean J Ophthalmol* 21:213-215
127. Karel I (2007) [The treatment of the exudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes]. *Cesk Slov Oftalmol* 63:311-319
128. Kelkar As, Kelkar Sb, Kelkar Ja et al. (2007) The use of intravitreal bevacizumab in neovascular glaucoma: a case report. *Bull Soc Belge Ophtalmol*:43-45
129. Kelman Se (2007) Intravitreal triamcinolone or bevacizumab for nonarteritic anterior ischemic optic neuropathy: do they merit further study? *J Neuroophthalmol* 27:161-163
130. Kenawy N, Groenwald C, Damato B (2007) Treatment of a vasoproliferative tumour with intravitreal bevacizumab (Avastin). *Eye* 21:893-894
131. Kenneth Te, Kertes Pj (2006) Ranibizumab in neovascular age-related macular degeneration. *Clin Interv Aging* 1:451-466
132. Kernt M, Neubauer As, Kampik A (2007) Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. *Acta Ophthalmol Scand* 85:119-120
133. Kernt M, Staehler M, Christian S et al. (2007) Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib((R)) treatment. *Acta Ophthalmol Scand*

134. Kernt M, Welge-Lussen U, Yu A et al. (2007) [Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells]. *Ophthalmologie* 104:965-971
135. Kiss C, Michels S, Prager F et al. (2006) Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. *Retina* 26:877-881
136. Kook D, Wolf A, Neubauer As et al. (2008) [Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD : Frequency and progress.]. *Ophthalmologie* 105:158-164
137. Kreutzer Tc, Alge Cs, Wolf Ah et al. (2008) Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. *Br J Ophthalmol* 92:351-355
138. Kriechbaum K, Michels S, Prager F et al. (2008) Intravitreal avastin for macular edema secondary to retinal vein occlusion - a prospective study. *Br J Ophthalmol*
139. Kumar A, Sinha S (2007) Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. *Indian J Ophthalmol* 55:451-455
140. Kumar A, Sinha S (2007) Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab. *Can J Ophthalmol* 42:335-336
141. La Cour M (2007) Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis? *Acta Ophthalmol Scand* 85:2-4
142. Ladas Id, Kotsolis Ai, Papakostas Td et al. (2007) Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration. *Retina* 27:891-896
143. Ladewig Ms, Karl Se, Hamelmann V et al. (2008) Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 246:17-25
144. Ladewig Ms, Ziemssen F, Jaissle G et al. (2006) [Intravitreal bevacizumab for neovascular age-related macular degeneration.]. *Ophthalmologie*
145. Ladewig Ms, Ziemssen F, Jaissle G et al. (2006) [Intravitreal bevacizumab for neovascular age-related macular degeneration]. *Ophthalmologie* 103:463-470
146. Laud K, Spaide Rf, Freund Kb et al. (2006) Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. *Retina* 26:960-963
147. Lazic R, Gabric N (2007) Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 245:68-73
148. Lazic R, Gabric N (2007) Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. *Ophthalmology* 114:1179-1185
149. Lazic R, Gabric N, Dekaris I et al. (2007) Photodynamic therapy combined with intravitreal bevacizumab (Avastin) in treatment of choroidal neovascularization secondary to age-related macular degeneration. *Coll Antropol* 31 Suppl 1:71-75
150. Meyer Ch, Scholl Hp, Eter N et al. (2008) Combined treatment of acute subretinal haemorrhages with intravitreal recombinant tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. *Acta Ophthalmol Scand*
151. Meyerle Cb, Freund Kb, Iturralde D et al. (2007) Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation. *Retina* 27:451-457
152. Michels S (2006) Is intravitreal bevacizumab (Avastin) safe? *Br J Ophthalmol* 90:1333-1334
153. Minnella Am, Savastano Cm, Ziccardi L et al. (2007) Intravitreal bevacizumab (Avastin((R))) in proliferative diabetic retinopathy. *Acta Ophthalmol Scand*



154. Mones Jm, Lopez Ma, Prieto Ja et al. (2007) Extrafoveal choroidal neovascularization secondary to wet age-related macular degeneration treated with intravitreal bevacizumab. *Ophthalmic Surg Lasers Imaging* 38:226-228
155. Montero Ja, Ruiz-Moreno Jm, De La Vega C (2007) Intravitreal bevacizumab for adult-onset vitelliform dystrophy: a case report. *Eur J Ophthalmol* 17:983-986
156. Moon Sj, Berger As, Tolentino Mj et al. (2007) Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis. *Ophthalmic Surg Lasers Imaging* 38:164-166
157. Moschos Mm, Brouzas D, Apostolopoulos M et al. (2007) Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Multifocal-ERG after use of bevacizumab in ARMD. *Doc Ophthalmol* 114:37-44
158. Moschos Mm, Moschos M (2008) Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT study. *Doc Ophthalmol* 116:147-152
159. Moshfeghi Aa, Rosenfeld Pj, Puliafito Ca et al. (2006) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. *Ophthalmology* 113:2002 e2001-2012
160. Neri P, Mariotti C, Mercanti L et al. (2007) Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin((R))). *Int Ophthalmol*
161. Nicolo M, Ghiglione D, Calabria G (2006) Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin). *Eur J Ophthalmol* 16:770-773
162. Niegel Mf, Schrage Nf, Christmann S et al. (2008) [Intravitreal bevacizumab for chronic central serous chorioretinopathy.]. *Ophthalmologe*
163. Niemeyer M, Hefner L, Jochmann C et al. (2007) [Intravitreal bevacizumab for recurring choroidal neovascularisation]. *Ophthalmologe* 104:158-160
164. Novack Gd (2008) Pharmacotherapy for the treatment of choroidal neovascularization due to age-related macular degeneration. *Annu Rev Pharmacol Toxicol* 48:61-78
165. Oshima Y, Sakaguchi H, Gomi F et al. (2006) Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. *Am J Ophthalmol* 142:155-158
166. Paccola L, Costa Ra, Folgosa Ms et al. (2008) Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). *Br J Ophthalmol* 92:76-80
167. Pai Sa, Shetty R, Vijayan Pb et al. (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. *Am J Ophthalmol* 143:601-606
168. Park Hj, Guy J (2007) Sixth nerve palsy post intravitreal bevacizumab for AMD: a new possibly causal relationship and complication? *Binocul Vis Strabismus Q* 22:209
169. Pedersen R, Soliman W, Lund-Andersen H et al. (2007) Treatment of choroidal neovascularization using intravitreal bevacizumab. *Acta Ophthalmol Scand* 85:526-533
170. Peters S, Heiduschka P, Julien S et al. (2008) Immunohistochemical localization of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye. *Br J Ophthalmol*
171. Peters S, Heiduschka P, Julien S et al. (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. *Am J Ophthalmol* 143:995-1002
172. Pieramici Dj, Avery Rl, Castellarin Aa et al. (2006) Case of anterior uveitis after intravitreal injection of bevacizumab. *Retina* 26:841-842

173. Priglinger Sg, Wolf Ah, Kreutzer Tc et al. (2007) Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. *Retina* 27:1004-1012
174. Quiroz-Mercado H, Ustariz-Gonzalez O, Martinez-Castellanos Ma et al. (2007) Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. *Semin Ophthalmol* 22:109-125
175. Rabena Md, Pieramici Dj, Castellarin Aa et al. (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. *Retina* 27:419-425
176. Reichel E (2005) Intravitreal bevacizumab for choroidal neovascularization and cystoid macular edema: a cost-effective treatment? *Ophthalmic Surg Lasers Imaging* 36:270-271
177. Rich Rm, Rosenfeld Pj, Puliafito Ca et al. (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. *Retina* 26:495-511
178. Rinaldi M, Dell'omo R, Romano Mr et al. (2007) Intravitreal bevacizumab for choroidal neovascularization secondary to angioid streaks. *Arch Ophthalmol* 125:1422-1423
179. Rizzo S, Genovesi-Ebert F, Di Bartolo E et al. (2008) Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). *Graefes Arch Clin Exp Ophthalmol*
180. Rodrigues Eb, Meyer Ch, Grumann a, Jr. et al. (2007) Tunneled scleral incision to prevent vitreal reflux after intravitreal injection. *Am J Ophthalmol* 143:1035-1037
181. Rodrigues Eb, Rossi Ee, Grumann Junior A et al. (2006) [Treatment of neovascular age-related macular degeneration with antiangiogenic drugs]. *Arq Bras Oftalmol* 69:756-765
182. Rodrigues Eb, Shiroma H, Meyer Ch et al. (2007) Metrorrhagia after intravitreal injection of bevacizumab. *Acta Ophthalmol Scand* 85:915-916
183. Ronan Sm, Yoganathan P, Chien Fy et al. (2007) Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. *Retina* 27:535-540
184. Rosenfeld Pj (2007) Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues. *Br J Ophthalmol* 91:128-130
185. Rosenfeld Pj (2006) Intravitreal avastin: the low cost alternative to lucentis? *Am J Ophthalmol* 142:141-143
186. Rosenfeld Pj, Fung Ae, Puliafito Ca (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. *Ophthalmic Surg Lasers Imaging* 36:336-339
187. Rosenfeld Pj, Moshfeghi Aa, Puliafito Ca (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. *Ophthalmic Surg Lasers Imaging* 36:331-335
188. Rosenfeld Pj, Rich Rm, Lalwani Ga (2006) Ranibizumab: Phase III clinical trial results. *Ophthalmol Clin North Am* 19:361-372
189. Rouvas Aa, Papakostas Td, Ladas Id et al. (2008) Enlargement of the hypofluorescent post photodynamic therapy treatment spot after a combination of photodynamic therapy with an intravitreal injection of bevacizumab for retinal angiomatous proliferation. *Graefes Arch Clin Exp Ophthalmol* 246:315-318
190. Ruiz-Moreno Jm, Gomez-Ulla F, Montero Ja et al. (2007) Intravitreal bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. *Eye*

191. Ruiz-Moreno Jm, Montero Ja, Lugo F et al. (2007) Intravitreal bevacizumab in recurrent diabetic vitreous haemorrhage after vitrectomy. *Acta Ophthalmol Scand*
192. Ruys J, De Laey Jj, Vanderhaeghen Y et al. (2007) Intravitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membrane. *Eye* 21:1433-1434
193. Sachdev N, Vishwanathan K, Gupta V et al. (2007) Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks. *Indian J Ophthalmol* 55:457-458
194. Sakaguchi H, Ikuno Y, Gomi F et al. (2007) Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. *Br J Ophthalmol* 91:161-165
195. Sangtam T, Vinekar A, Maheshwar B et al. (2007) Intravitreal bevacizumab (Avastin) for post-laser photocoagulation anterior segment ischemia in aggressive posterior retinopathy of prematurity. *Indian J Ophthalmol* 55:317; author reply 317-318
196. Sawada O, Kawamura H, Kakinoki M et al. (2007) Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. *Arch Ophthalmol* 125:1363-1366
197. Schaal Kb, Engler C, Schutt F et al. (2008) [Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD.]. *Ophthalmologe*
198. Schaal Kb, Hoh Ae, Scheuerle A et al. (2007) [Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion]. *Ophthalmologe* 104:285-289
199. Schulze S, Mennel S (2007) [Treatment of idiopathic juxtafoveolar retinal telangiectasis with bevacizumab (avastin)]. *Klin Monatsbl Augenheilkd* 224:787-790
200. Schwartz Sg, Hickey M, Puliafito Ca (2006) Bilateral CRAO and CRVO from thrombotic thrombocytopenic purpura: OCT findings and treatment with triamcinolone acetonide and bevacizumab. *Ophthalmic Surg Lasers Imaging* 37:420-422
201. Scott Iu, Bressler Nm, Bressler Sb et al. (2008) Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. *Retina* 28:36-40
202. Scott Iu, Edwards Ar, Beck Rw et al. (2007) A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. *Ophthalmology* 114:1860-1867
203. Seth Rk, Stoessel Km, Adelman Ra (2007) Choroidal neovascularization associated with West Nile virus chorioretinitis. *Semin Ophthalmol* 22:81-84
204. Shah Cp, Hsu J, Garg Sj et al. (2006) Retinal pigment epithelial tear after intravitreal bevacizumab injection. *Am J Ophthalmol* 142:1070-1072
205. Shah N, Shah U (2008) Combination of photodynamic therapy with intravitreal bevacizumab for post-peribulbar anesthesia (penetrating trauma)-persistent choroidal neovascular membrane. *Indian J Ophthalmol* 56:163-164
206. Shah Pk, Narendran V, Tawansy Ka et al. (2007) Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. *Indian J Ophthalmol* 55:75-76
207. Shahar J, Avery Rl, Heilweil G et al. (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). *Retina* 26:262-269
208. Shaikh S, Olson Jc, Richmond Pp (2007) Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. *Indian J Ophthalmol* 55:470-472
209. Shanmugam Mp, Mythri Hm, Shetty Ns (2007) Intravitreal bevacizumab for parafoveal telangiectasia-associated choroidal neovascular membrane. *Indian J Ophthalmol* 55:490-491

210. Shetty R, Pai Sa, Vincent A et al. (2008) Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. *Doc Ophthalmol* 116:129-135
211. Shima C, Sakaguchi H, Gomi F et al. (2007) Complications in patients after intravitreal injection of bevacizumab. *Acta Ophthalmol Scand*
212. Silva Paula J, Jorge R, Alves Costa R et al. (2006) Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. *Acta Ophthalmol Scand* 84:556-557
213. Siqueira Rc, Costa Ra, Scott Iu et al. (2006) Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. *Acta Ophthalmol Scand* 84:834-835
214. Soheiliani M, Ramezani A, Bijanzadeh B et al. (2007) Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. *Retina* 27:1187-1195
215. Soliman W, Lund-Andersen H, Larsen M (2006) Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization. *Acta Ophthalmol Scand* 84:707-708
216. Soliman W, Vinten M, Sander B et al. (2007) Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. *Acta Ophthalmol Scand*
217. Spaide Rf, Fisher Yl (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. *Retina* 26:275-278
218. Spaide Rf, Laud K, Fine Hf et al. (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. *Retina* 26:383-390
219. Spandau U, Wickenhauser A, Rensch F et al. (2007) Intravitreal bevacizumab for branch retinal vein occlusion. *Acta Ophthalmol Scand* 85:118-119
220. Spandau Uh, Ihloff Ak, Jonas Jb (2006) Intravitreal bevacizumab treatment of macular oedema due to central retinal vein occlusion. *Acta Ophthalmol Scand* 84:555-556
221. Spandau Uh, Jonas Jb (2007) Intravitreal bevacizumab for peripapillary classic subretinal neovascularization. *Acta Ophthalmol Scand* 85:340-341
222. Spandau Uh, Jonas Jb (2006) Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration. *Am J Ophthalmol* 142:1068-1070
223. Spitzer Ms, Wallenfels-Thilo B, Sierra A et al. (2006) Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. *Br J Ophthalmol* 90:1316-1321
224. Spitzer Ms, Yoeruek E, Sierra A et al. (2007) Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. *Graefes Arch Clin Exp Ophthalmol* 245:1837-1842
225. Spitzer Ms, Ziemssen F, Yoeruek E et al. (2008) Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. *J Cataract Refract Surg* 34:70-75
226. Stewart Mw (2007) Predicted biologic activity of intravitreal bevacizumab. *Retina* 27:1196-1200
227. Stifter E, Michels S, Prager F et al. (2007) Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. *Am J Ophthalmol* 144:886-892

228. Subramanyam A, Phatak S, Chudgar D (2007) Large retinal pigment epithelium rip following serial intravitreal injection of avastin in a large fibrovascular pigment epithelial detachment. *Indian J Ophthalmol* 55:483-486
229. Tan Cs, Sanjay S, Eong Kg (2007) Charles Bonnet syndrome (visual hallucinations) after intravitreal avastin injection for age-related macular degeneration. *Am J Ophthalmol* 144:330; author reply 330-331
230. Tang Sb, Liang Xl, Hu J et al. (2007) [A preliminary study on intravitreal injection of bevacizumab for treatment of neovascular age-related macular degeneration]. *Zhonghua Yan Ke Za Zhi* 43:890-896
231. Yoganathan P, Deramo Va, Lai Jc et al. (2006) Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. *Retina* 26:994-998
232. Ziemssen F, Bartz-Schmidt Ku, Grisanti S (2006) [(Side) effects of VEGF inhibition.]. *Ophthalmologe*
233. Ziemssen F, Bartz-Schmidt Ku, Grisanti S (2006) [(Side) effects of VEGF inhibition.]. *Ophthalmologe* 103:484-492
234. Ziemssen F, Deuter Cm, Stuebiger N et al. (2007) Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). *Graefes Arch Clin Exp Ophthalmol* 245:917-918
235. Ziemssen F, Grisanti S, Bartz-Schmidt Ku (2006) The international intravitreal bevacizumab safety survey. *Br J Ophthalmol* 90:1440-1441
236. Ziemssen F, Luke M, Messias A et al. (2007) Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. *Int Ophthalmol*
237. Ziemssen F, Voelker M, Altpeter E et al. (2007) Intravitreal bevacizumab treatment of radiation maculopathy due to brachytherapy in choroidal melanoma. *Acta Ophthalmol Scand* 85:579-580
238. Ziemssen F, Voelker M, Inhoffen W et al. (2007) Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy. *Eye* 21:1125-1126
239. Ziemssen F, Warga M, Neuhann Im et al. (2006) Does intravitreal injection of bevacizumab have an effect on the blood-aqueous barrier function? *Br J Ophthalmol* 90:922